Quarterly report · Q2
3151.TEDINET S100PL90
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥289.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥577.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥285.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥730m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥934m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥316.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥313.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥327.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥212.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥213.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥103.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥100.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥105.6bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥23.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.4bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥27.42 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.4 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.67 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.01 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥146m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥6.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥6.4bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥58m |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥278.2bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥273.0bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥607m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥32m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.3bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥178m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥292.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥287.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥819m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥295.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥289.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥672m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥97m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥5.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥5.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | ¥19m |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥273.4bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥269.1bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥739m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1m |
| jpcrp040300-q2r_E22440-000Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥83m |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥189m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥287.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥283.3bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.3bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥290.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥285.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥915m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Allowance for doubtful accounts ca | Prior1YearInstant | -50000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -830000000 | JPY |
| Current assets | Prior1YearInstant | 198532000000 | JPY |
| Current assets | CurrentQuarterInstant | 200920000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 19303000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 20917000000 | JPY |
| Land | Prior1YearInstant | 20735000000 | JPY |
| Land | CurrentQuarterInstant | 20654000000 | JPY |
| Other net ppe | Prior1YearInstant | 5722000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 3947000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 45761000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 45519000000 | JPY |
| Goodwill | Prior1YearInstant | 2874000000 | JPY |
| Goodwill | CurrentQuarterInstant | 2702000000 | JPY |
| Other ia | Prior1YearInstant | 2162000000 | JPY |
| Other ia | CurrentQuarterInstant | 2047000000 | JPY |
| Intangible assets | Prior1YearInstant | 5036000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 4750000000 | JPY |
| Investment securities | Prior1YearInstant | 47508000000 | JPY |
| Investment securities | CurrentQuarterInstant | 53263000000 | JPY |
| Other ioa | Prior1YearInstant | 16771000000 | JPY |
| Other ioa | CurrentQuarterInstant | 12434000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -576000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -456000000 | JPY |
| Investments and other assets | Prior1YearInstant | 63703000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 65241000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 114501000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 115511000000 | JPY |
| Assets | Prior1YearInstant | 313033000000 | JPY |
| Assets | CurrentQuarterInstant | 316432000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 176685000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 179248000000 | JPY |
| Short term loans payable | Prior1YearInstant | 990000000 | JPY |
| Short term loans payable | CurrentQuarterInstant | 990000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 970000000 | JPY |
| Current portion of long term loans payable | CurrentQuarterInstant | 970000000 | JPY |
| Income taxes payable | Prior1YearInstant | 2399000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 1067000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 1542000000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 1482000000 | JPY |
| Other cl | Prior1YearInstant | 7505000000 | JPY |
| Other cl | CurrentQuarterInstant | 7471000000 | JPY |
| Current liabilities | Prior1YearInstant | 190092000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 191230000000 | JPY |
| Long term loans payable | Prior1YearInstant | 7760000000 | JPY |
| Long term loans payable | CurrentQuarterInstant | 7275000000 | JPY |
| Other provision ncl | Prior1YearInstant | 244000000 | JPY |
| Other provision ncl | CurrentQuarterInstant | 238000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 2629000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 590000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |